| Literature DB >> 22078495 |
Philipp Widmann1, Karin Nuernberg, Christa Kuehn, Rosemarie Weikard.
Abstract
BACKGROUND: The intramuscular fat deposition and the fatty acid profiles of beef affect meat quality. High proportions of unsaturated fatty acids are related to beef flavor and are beneficial for the nutritional value of meat. Moreover, a variety of clinical and epidemiologic studies showed that particularly long-chain omega-3 fatty acids from animal sources have a positive impact on human health and disease.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22078495 PMCID: PMC3260110 DOI: 10.1186/1471-2156-12-96
Source DB: PubMed Journal: BMC Genet ISSN: 1471-2156 Impact factor: 2.797
Figure 1QTL for the relative content of n-3 long chain PUFA (n-3 LC PUFA) on BTA27. Solid boxes: ACSL1 c.481-233A>G effect not included in the model, open boxes: ACSL1 c.481-233A>G included in the model as a fixed effect. LRT significance threshold is indicated by a dashed line (α = 0.05: 7.23).
Figure 2Structure of the bovine . Reference mRNA sequence: NM_001076085.1. SNPs included in the association analysis are bold framed.
Identified SNPs within the ACSL1 locus and positions on the bovine genome assemblies
| SNP ID | Gene region | Variation relative to reference sequence | Position on NW_001494406.2 (Btau4.2) | Position on NW_003104605.1 (UMD_3.1) | Allele | SNP accession number (dbSNP, NCBI ss#) |
|---|---|---|---|---|---|---|
| c.-569_570del AC | Promoter | Indel TG | 1918795 | 389858 | Not analyzed | ss469271165 |
| c.-224_225del GG | Promoter | Indel (C)5-7 | 1918451 | 389615 | Not analyzed | ss469271166 |
| c.-196G>A | Promoter | C>T | 1918422 | 3894586 | Not analyzed | ss469271167 |
| c.-167G>C | Promoter | C>G | 1918393 | 3894557 | Not analyzed | ss469271168 |
| c.-151G>C | Promoter | C>G | 1918377 | 3894541 | Not analyzed | ss469271169 |
| Promoter | C>T | 1918348 | 3894512 | 0.67 (G)/0.33 (A) | ss469271170 | |
| Intron 5 | T>C | 1876389 | 3852106 | 0.73 (A)/0.27 (G) | ss469271171 | |
| Exon 6 | G>C | 1876121 | 3852284 | 0.57 (C)/0.43 (G) | ss469271172 | |
| Intron 6 | G>C | 1875943 | 3852552 | 0.33 (C)/0.67 (G) | ss469271173 | |
| Exon 7 | T>C | 1875838 | 3852001 | 0.07 (G)/0.94 (A) | ss469271174 | |
| Intron 9 | A>C | 1871919 | 3848082 | 0.75 (T)/0.21 (G)5 | ss469271175 | |
| Intron 13 | G>A | 1864210 | 3840373 | 0.24 (T)/0.76 (C) | ss469271176 | |
| c.1525-131C>T | Intron 16 | G>A | 1859370 | 3835533 | Not analyzed | ss469271177 |
| Exon 20 | A>C | Not annotated | 3831586 | 0.75 (T)/0.25 (G) | ss469271178 | |
| Intron 20 | C>T | Not annotated | 3831509 | 0.24 (A)/0.76 (G) | ss469271179 | |
| c.2099+1023del A | 3'UTR | Indel A | 1853870 | 3829944 | Not analyzed | ss469271180 |
| c.2099+1030 C>A | 3'UTR | C>A | 1853863 | 3829937 | Not analyzed | ss469271181 |
| c.2099+1032 A>C | 3'UTR | A>C | 1853861 | 3829935 | Not analyzed | ss469271182 |
| c.2099+1034 C>A | 3'UTR | C>A | 1853859 | 3829933 | Not analyzed | ss469271183 |
*SNP nomenclature according to the translation start codon ATG, reference sequence NM_001076085.1. SNPs marked in bold were included in the association analysis. Genomic positions of the SNPs were inferred from the current versions of the refererence and alternative bovine genome assemblies Btau4.2 and UMD_3.1 available at NCBI (http://www.ncbi.nlm.nih.gov/genome/guide/cow/index.html).
Association of the SNP in intron 5 of the ACSL1 gene (c.481-233A>G) with variation in intramuscular fatty acid composition and fat content
| Model without IMF as covariate | Model with IMF as covariate | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trait* | LRT | p-value | Effect allele A | SE | Effect allele G | SE | Var [%]** | LRT | p-value | Effect allele A | SE | Effect allele G | SE |
| Total FA [mg] | 6.2 | 0.0130 | 3.70 | 0.07 | 3.88 | 0.07 | 3.8 | 0.0507 | |||||
| MUFA [mg] | 5.9 | 0.0154 | 3.29 | 0.08 | 3.48 | 0.09 | 2.9 | 0.0874 | |||||
| n-3 FA [%] | 9.7 | 0.0018a | 0.16 | 0.05 | 0.01 | 0.06 | 11.4 | 5.8 | 0.0159 | 0.42 | 0.04 | 0.36 | 0.04 |
| PUFA [%] | 7.1 | 0.0079b | 1.12 | 0.05 | 0.98 | 0.06 | 3.5 | 3.9 | 0.0477 | ||||
| n-3 LC PUFA [%]# | 6.7 | 0.0099b | 0.24 | 0.03 | 0.16 | 0.04 | 3.4 | 3.5 | 0.0628 | ||||
| C18:1trans-11 [mg] | 10.5 | 0.0012a | 1.31 | 0.10 | 1.63 | 0.12 | 6.5 | 8.1 | 0.0045a | 0.86 | 0.09 | 1.07 | 0.10 |
| C22:5n-3 [%]# | 7.2 | 0.0071 b | 0.16 | 0.02 | 0.11 | 0.03 | 3.6 | 5.9 | 0.0150 | 0.27 | 0.02 | 0.23 | 0.02 |
| PUFA/SFA | 7.3 | 0.0069b | -0.79 | 0.06 | -0.94 | 0.07 | 3.6 | 4.2 | 0.0407 | ||||
| P/S | 6.7 | 0.0099b | -1.02 | 0.05 | -1.15 | 0.06 | 3.2 | 3.2 | 0.0758 | ||||
| LA/ALA | 4.9 | 0.0265 | 1.03 | 0.03 | 0.97 | 0.03 | 1.9 | 0.1720 | |||||
| IMF [%] | 3.1 | 0.0776 | 1.11 | 0.18 | 1.42 | 0.21 | 1.7 | ||||||
*Trait data log-transformed, &absolute content of fatty acids (mg/100 g of skeletal muscle), #relative content of fatty acids (percentage of the respective fatty acid fraction relative to total fatty acid amount)
LTR: likelihood ratio test, p: significancy of allelic effects, Var: variance explained, SE: standard error, aq-value <0.05, bq-value <0.1, **% variance in the model calculated as the relative reduction of the residual variance due to including the SNP in the model [47].
Allelic effects of the ACSL1 SNP (c.481-233A>G) on different FA fractions: n-3 fatty acids (n-3 FA = C18:3n-3 + C18:4n-3 + C20:5n-3 + C22:5n-3 + C22:6n-3), poly-unsaturated fatty acids (PUFA = n-3 FA + n-6 FA [C18:2n-6 + C18:3n-6 + C20:2n-6 + C20:3n-6 + C20:4n-6 + C22:2n-6 + C22:4n-6]), n-3 long-chain PUFA (n-3 LC-PUFA = C20:3n-3 + C22:6n-3 + C22:5n-3 + C20:5n-3), total FA, mono-unsaturated fatty acids (MUFA), docosapentaenoic fatty acid (DPA, C22:5n-3), trans vaccenic acid (TVA, C18:1trans-11) and the ratios: PUFA/SFA (saturated fatty acids = C12:0 + C14:0 + C16:0 + C17:0 + C18:0 + C20:0 + C24:0), P/S (C18:2 n-6 + C18:3 n-3/C14:0 + C16:0 + C18:0), LA/ALA (C18:2 n-6/C18:3 n-3), and the intramuscular fat content (IMF).
Phenotypic traits characterizing fatty acid composition in skeletal muscle
| Trivial name | Abbreviation | Mean of absolute | SD | Mean of relative | SD |
|---|---|---|---|---|---|
| Lauric acid | C12:0 | 2.83* | 1.80 | 0.10 | 0.04 |
| Myristoleic acid | C14:1cis-9 | 18.53 | 17.85 | 0.62 | 0.31 |
| Myristic acid | C14:0 | 92.12* | 65.50 | 3.10* | 0.66 |
| Palmitoleic acid | C16:1cis-9 | 109.33* | 76.59 | 3.73 | 0.83 |
| Palmitic acid | C16:0 | 823.94* | 490.88 | 28.77 | 1.86 |
| Heptadecenoic acid | C17:1cis-10 | 23.48* | 12.51 | 0.85 | 0.18 |
| Margaric acid | C17:0 | 34.94* | 18.13 | 1.26* | 0.25 |
| Stearic acid | C18:0 | 373.40* | 199.95 | 4.96* | 1.80 |
| Oleic acid | C18:1cis-9 | 981.37* | 578.52 | 34.35 | 2.60 |
| Vaccenic acid | C18:1cis-11 | 43.60* | 30.60 | 13.41 | 1.65 |
| trans Vaccenic acid | C18:1trans-11 | 28.40* | 20.18 | 1.52* | 0.33 |
| Linoleic acid (LA) | C18:2n-6 | 121.45* | 29.94 | 0.99* | 0.43 |
| Linolelaidic acid | C18:2trans-9, trans-12 | 4.11* | 3.39 | 0.11 | 0.13 |
| Conjugated linoleic acid | CLAcis-9, trans-11 | 5.99* | 4.73 | 0.20 | 0.09 |
| α-Linolenic acid (ALA) | C18:3n-3 | 12.99 | 4.97 | 0.50* | 0.14 |
| Stearidonic acid (SDA) | C18:4n-3 | 2.70 | 3.36 | 0.15 | 0.10 |
| Arachidic acid | C20:0 | 2.94 | 1.90 | 0.11 | 0.06 |
| Eisosenoic acid | C20:1n-9 | 4.21* | 2.80 | 0.35 | 0.15 |
| Eisosatrienoic acid (ETE) | C20:3n-3 | 8.15* | 1.86 | 0.11* | 0.05 |
| Arachidonic acid (AA) | C20:4n-6 | 33.89 | 7.60 | 1.48* | 0.74 |
| Timnodonic acid, EPA | C20:5n-3 | 2.41* | 0.70 | 0.14* | 0.03 |
| Erucic acid | C22:1n-9 | 0.46* | 0.24 | 0.02* | 0.01 |
| Adrenic acid | C22:4n-6 | 6.20 | 1.53 | 0.28 | 0.13 |
| Clupadonic acid, DPA | C22:5n-3 | 6.51* | 1.34 | 0.26* | 0.11 |
| Cervonic acid, DHA | C22:6n-3 | 0.92 | 0.45 | 0.04 | 0.03 |
| Lignoceric acid | C24:0 | 0.82 | 0.44 | 0.03* | 0.02 |
| ∑ Saturated fatty acids | SFA | 1352.06* | 777.93 | 47.55 | 2.38 |
| ∑ Unsaturated fatty acids | UFA | 1463.62* | 777.61 | 52.45 | 2.38 |
| ∑ Polyunsaturated fatty acids | PUFA | 208.34* | 44.62 | 8.57* | 3.02 |
| ∑ Monounsaturated fatty acids | MUFA | 1208.85* | 726.67 | 42.19* | 3.16 |
| ∑ trans fatty acids | TFA | 43.92* | 24.70 | 1.58 | 0.47 |
| ∑ n-3 fatty acids | n-3FA | 24.75 | 6.42 | 1.01* | 0.35 |
| ∑ n-3 long-chain PUFA | n-3 LCPUFA | 9.58 | 2.21 | 0.42* | 0.20 |
| ∑ n-6 fatty acids | n-6FA | 167.28* | 34.88 | 6.94 | 2.64 |
| ∑ n-6 long-chain PUFA | n-6 LCPUFA | 40.09 | 8.62 | 1.78 | 0.85 |
| ∑ Total fatty acids | FA | 2743.81* | 1524.08 | ||
| Ratio n-6/n-3 | n-6/n-3 | 6.96 | 1.42 | ||
| Ratio MUFA/SFA | MUFA/SFA | 0.89 | 0.09 | ||
| Ratio PUFA/SFA | PUFA/SFA | 0.18* | 0.07 | ||
| Ratio P/S | P/S | 0.12* | 0.05 | ||
| Ratio C18:2n-6/C18:3n-3 | LA/ALA | 9.86* | 2.51 | ||
| Δ9-desaturase index MUFA | Δ9MUFA | 46.39 | 2.56 | ||
| Δ9-desaturase index C14 | Δ9C14 | 16.31 | 6.65 | ||
| Δ9-desaturase index C16 | Δ9C16 | 11.40 | 2.08 | ||
| Δ9-desaturase index C18 | Δ9C18 | 72.16 | 3.34 | ||
| Intramuscular fat content | IMF | 2.56 | 1.13 |
SD: standard deviation
*Data displaying distributions significantly different from normality (p < 0.01) were log-transformed.
SFA = C12:0 + C14:0 + C16:0 + C17:0 + C18:0 + C20:0 + C24:0
MUFA = C14:1 + C16:1 + C17:1 + C18:1 + C20:1 + C22:1 + C18:1cis-9 + C18:1cis-11 + C18:1trans-11
UFA = MUFA + PUFA
Total FA = sum of all fatty acids determined
n-3FA = C18:3n-3 + C18:4n-3 + C20:3n-3 + C20:5n-3 + C22:5n-3 + C22:6n-3
n-6FA = C18:2n-6 + C18:3n-6 + C20:2n-6 + C20:3n-6 + C20:4n-6 + C22:2n-6 + C22:4n-6
PUFA = n-3FA + n-6FA
n-3 LC-PUFA = C20:3n-3 + C22:6n-3 + C22:5n-3 + C20:5n-3
TFA = C18:1trans-11 + C18:2trans-9, trans-12
LA/ALA = C18:2n-6/C18:3n-3
P/S = C18:2 n-6 + C18:3 n-3/C14:0 + C16:0 + C18:0
Δ9MUFA = [(C14:1 + C16:1 + C17:1 + C18:1cis-9 + CLAcis-9, trans-11)/(C14:1 + C16:1 + C17:1 + C18:1cis-9 +
C18:1trans-11 + C14:0 + C16:0 + C17:0 + C18:0 + CLAcis-9, trans-11)] × 100
Δ9C14 = [C14:1/(C14:0 + C14:1)] × 100
Δ9C16 = [C16:1/(C16:0 + C16:1)] × 100
Δ9C18 = [(C18:1cis-9 + CLAcis-9, trans-11/(C18:0 + C18:1cis-9 + C18:1trans-11 + CLAcis-9, trans-11)] × 100
Primer sequences for the bovine ACSL1 gene applied for annotation confirmation, screening for polymorphisms and genotyping
| Primer | Sequence (5' → 3') | Gene region | Amplicon (bp) | Position in reference sequence | AccNo. of reference sequence | Application* |
|---|---|---|---|---|---|---|
| ACSL1_F1 | CCGAGCCCCAACCGAGAC | intron 1 -promoter | 844 | 1918181 - 1918198 | NW_001494406.2 | SNP |
| ACSL1_E1_F3 | GACCCGAGCCCCAACCGAG | intron 1 -promoter | 497 | 1918178 - 1918196 | NW_001494406.2 | SNP |
| ACSL1_E1SR | GGACTGCCCTGGATTTCACAAG | promoter | 413 | 1918612 - 1918633 | NW_001494406.2 | SNP |
| ACSL1_F2 | TCGCTGCTGAAGTCCTGTCTG | exon 2 | 501 | 1897290 - 1897310 | NW_001494406.2 | SNP |
| ACSL1_F3 | TTGCGTGGGAGAGAGTTGTG | exon 3 | 384 | 1882758 - 1882777 | NW_001494406.2 | SNP |
| ACSL1_F4 | GCATCCACACTCCATAGAAAC | exon 4 | 345 | 1881998 - 1882018 | NW_001494406.2 | SNP |
| ACSL1_F5 | ATGAAAGGGAAAAGTGAAAGTG | exon 5 | 457 | 1878288 - 1878309 | NW_001494406.2 | SNP |
| ACSL1_F6 | CGGCTGGAAGTAAAGAGACAC | exon 6 | 574 | 1875840 - 1875860 | NW_001494406.2 | SNP |
| ACSL1_F7 | GTTCTCTTTTACAGGACCAG | exon 7 | 600 | 1875542 - 1875561 | NW_001494406.2 | SNP |
| ACSL1_F8_9 | TGGGTGATGTAAATGTGTGAGG | exons | 750 | 1872567 - 1872588 | NW_001494406.2 | SNP |
| ACSL1_F10 | ATCTGTATTTCAGGTACTGTTTC | exon 10 | 287 | 1871656 - 1871678 | NW_001494406.2 | SNP |
| ACSL1_F11 | TACACACTTGAACTTACCAG | exon 11 | 314 | 1869171 - 1869190 | NW_001494406.2 | SNP |
| ACSL1_F12 | TCTGTATTGTGCCTTCTGATG | exon 12 | 371 | 1866801 - 1866821 | NW_001494406.2 | SNP |
| ACSL1_F13 | TCTCACACAATAAAGGGGTAGG | exon 13 | 516 | 1864669 - 1864690 | NW_001494406.2 | SNP |
| ACSL1_F14 | AAGCCGCCCAGGAATAACAC | exon 14 | 516 | 1863888 - 1863907 | NW_001494406.2 | SNP |
| ACSL1_F15 | GACTTGTGTTTATTTCTGCCTG | exon 15 | 524 | 1862774 - 1862795 | NW_001494406.2 | SNP |
| ACSL1_F16 | TGCTGAGAAGTGGCTGGTTAC | exon 16 | 247 | 1860135 - 1860155 | NW_001494406.2 | SNP |
| ACSL1_F17 | ATGCGAGGGAGAAAGAGG | exon 17 | 427 | 1859039 - 1859056 | NW_001494406.2 | SNP |
| ACSL1_F18 | GGCAAACTTCCCATTACACTG | exon 18 | 512 | 1857386 - 1857406 | NW_001494406.2 | SNP |
| ACSL1_F19_20 | GCCAAAGCACACCACTCTC | exons 19-20 | 517 | 139425 - 139443 | NW_930554.1 | SNP |
| ACSL1_F21 | CACCCGCCTTTGTAACTG | exon 21 | 548 | 138819 - 138836 | NW_930554.1 | SNP |
| ACSL1_UTR_F31 | AAACCCTCTGGTCCTCTTGCG | exon 21 | 404 | 138633 - 138653 | NW_930554.1 | SNP |
| ACSL1_UTR_F2 | GAGTTTTCCAGATTCCTATGTCC | exon 21 | 650 | 137966 - 137988 | NW_930554.1 | SNP |
| ACSL1_UTR_F11 | ATGCGACTGCTGACATGAAAAAC | exon 21 | 527 | 137530 - 137552 | NW_930554.1 | SNP |
| ACSL1_E1_F3 | GACCCGAGCCCCAACCGAG | intron 1-promoter | 220 | 1918178 - 1918196 | NW_001494406.2 | GT |
| ACSL1_F7 | GTTCTCTTTTACAGGACCAG | exon 7 | 600 | 1875542 - 1875561 | NW_001494406.2 | GT |
| ACSL1_E1_F5 | GGAGGGAACTCGGGGAGCC | promoter | 451 | 1918052 - 1918070 | NW_001494406.2 | GT |
| ACSL1_E1_F2 | CGGAGGAGACTGTGGCTTAG | exons | 505 | 38 - 58 | NM_001076085.1 | cDNA |
| ACSL1_E5_F1 | CAGTTTATTGGCATCTTCGCTC | exons | 649 | 519 - 541 | NM_001076085.1 | cDNA |
| ACSL1_E11_F2 | CCATATGTTTGAGAGAGTTGTAG | exons 11-18 | 735 | 1046-1069 | NM_001076085.1 | cDNA |
| ACSL1_E17_F2 | CTGGATAAAGACGGCTGGTTG | exons 17-21 | 399 | 1665 - 1686 | NM_001076085.1 | cDNA |
| ACSL1_E21_R3 | GTCAAACTCCCCTCCGCTTC | exons 17-21 | 540 | 2185 - 2205 | NM_001076085.1 | cDNA, RT |
| ACSL1_E21_R4 | CAGAAAGAGCAAAGTCCTAACC | 2454 - 2476 | NM_001076085.1 | cDNA, RT |
* cDNA: analysis of cDNA structure, RT: reverse transcription, GT: genotyping, SNP: screening for polymorphisms